AC Immune (NASDAQ:ACIU) Posts Quarterly Earnings Results, Misses Estimates By $0.09 EPS

AC Immune (NASDAQ:ACIU) issued its earnings results on Wednesday. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.09), FiscalAI reports. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%.The business had revenue of $18.67 million during the quarter, compared to analysts’ expectations of $34.08 million.

AC Immune Trading Up 1.5%

Shares of ACIU stock traded up $0.04 during trading hours on Wednesday, reaching $2.31. The company’s stock had a trading volume of 117,425 shares, compared to its average volume of 291,557. The company has a current ratio of 0.87, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. AC Immune has a one year low of $2.03 and a one year high of $4.00. The stock has a market capitalization of $234.59 million, a P/E ratio of -2.81 and a beta of 1.59. The firm’s fifty day simple moving average is $2.39 and its 200 day simple moving average is $2.79.

Analyst Ratings Changes

A number of research firms have recently weighed in on ACIU. Weiss Ratings lowered AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. BTIG Research reissued a “buy” rating and set a $8.00 price objective on shares of AC Immune in a research note on Monday, May 4th. Finally, HC Wainwright restated a “buy” rating on shares of AC Immune in a report on Wednesday, July 1st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, AC Immune has a consensus rating of “Hold” and an average price target of $7.50.

Insider Activity at AC Immune

In related news, CEO Andrea Pfeifer sold 10,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $2.79, for a total value of $27,900.00. Following the completion of the sale, the chief executive officer owned 3,820,288 shares of the company’s stock, valued at $10,658,603.52. This trade represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. EFG International AG purchased a new stake in shares of AC Immune in the 4th quarter worth about $41,000. Private Advisor Group LLC purchased a new position in shares of AC Immune during the third quarter valued at about $48,000. Goldman Sachs Group Inc. raised its stake in AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after buying an additional 5,920 shares in the last quarter. Susquehanna International Group LLP bought a new position in AC Immune in the third quarter worth about $63,000. Finally, Sei Investments Co. bought a new stake in AC Immune during the 2nd quarter valued at approximately $51,000. 51.36% of the stock is currently owned by institutional investors.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.